BNP Paribas Exane Issues Positive Forecast for Corteva (NYSE:CTVA) Stock Price

Corteva (NYSE:CTVA) had its target price boosted by analysts at BNP Paribas Exane from $72.00 to $74.00 in a report released on Monday,MarketScreener reports. BNP Paribas Exane’s target price would suggest a potential downside of 3.50% from the stock’s current price.

Several other research analysts have also recently weighed in on CTVA. Bank of America upped their price objective on shares of Corteva from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Oppenheimer set a $86.00 price target on shares of Corteva in a research note on Thursday, February 5th. Royal Bank Of Canada increased their price target on shares of Corteva from $80.00 to $89.00 and gave the stock an “outperform” rating in a report on Thursday, February 5th. CICC Research raised their price objective on shares of Corteva from $70.00 to $80.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. Finally, Mizuho lifted their price objective on shares of Corteva from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Tuesday, February 17th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have issued a Hold rating to the stock. According to data from MarketBeat.com, Corteva presently has a consensus rating of “Moderate Buy” and a consensus target price of $82.90.

Corteva Price Performance

Corteva stock traded down $0.28 during midday trading on Monday, hitting $76.68. 188,086 shares of the company’s stock were exchanged, compared to its average volume of 4,035,306. Corteva has a 52-week low of $53.40 and a 52-week high of $80.90. The stock has a 50-day moving average price of $73.00 and a two-hundred day moving average price of $69.00. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.96 and a current ratio of 1.43. The company has a market cap of $51.57 billion, a P/E ratio of 48.53, a PEG ratio of 2.63 and a beta of 0.72.

Corteva (NYSE:CTVA) last announced its earnings results on Tuesday, February 3rd. The company reported $0.22 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.22. The business had revenue of $3.91 billion for the quarter, compared to analyst estimates of $4.23 billion. Corteva had a return on equity of 9.06% and a net margin of 6.29%.The company’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same period in the prior year, the company earned $0.32 EPS. Corteva has set its FY 2026 guidance at 3.450-3.700 EPS. On average, equities research analysts forecast that Corteva will post 2.96 earnings per share for the current year.

Insiders Place Their Bets

In other Corteva news, insider Brian Titus sold 8,311 shares of the business’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $76.55, for a total value of $636,207.05. Following the completion of the sale, the insider directly owned 8,090 shares of the company’s stock, valued at $619,289.50. The trade was a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 0.15% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Activest Wealth Management boosted its holdings in Corteva by 118.3% during the 3rd quarter. Activest Wealth Management now owns 369 shares of the company’s stock valued at $25,000 after acquiring an additional 200 shares during the period. JPL Wealth Management LLC bought a new stake in Corteva in the third quarter valued at approximately $25,000. True Wealth Design LLC lifted its position in Corteva by 209.5% in the third quarter. True Wealth Design LLC now owns 390 shares of the company’s stock valued at $26,000 after purchasing an additional 264 shares during the last quarter. Total Investment Management Inc. purchased a new stake in shares of Corteva during the second quarter valued at approximately $27,000. Finally, Garton & Associates Financial Advisors LLC bought a new position in shares of Corteva in the fourth quarter worth approximately $27,000. Hedge funds and other institutional investors own 81.54% of the company’s stock.

Corteva Company Profile

Corteva, Inc (NYSE: CTVA) is an independent global agriculture company that was established as a publicly traded firm in mid‑2019 following the separation of the agriculture businesses from DowDuPont. The company focuses on delivering technologies and products that help farmers increase productivity and manage crop health. Corteva’s operations combine seed genetics, crop protection chemistries, digital tools and biological solutions to address the full cycle of crop production.

Core business activities include research and development of seed genetics and trait technologies, formulation and sale of crop protection products (such as herbicides, insecticides and fungicides), and the development of seed treatments and biologicals.